<DOC>
	<DOCNO>NCT02808052</DOCNO>
	<brief_summary>This Phase 1 , open-label , single-dose study safety , tolerability , pharmacokinetics Minocin® ( minocycline ) injection subject renal insufficiency .</brief_summary>
	<brief_title>Evaluate Safety Pharmacokinetics Minocin ( Minocycline ) Injection Subjects With Renal Insufficiency</brief_title>
	<detailed_description>The purpose study collect safety , tolerability , pharmacokinetics ( PK ) data single dose Minocin® ( minocycline ) Injection subject renal insufficiency subject receive hemodialysis therapy . The safety , tolerability , PK data support compound potential clinical candidate Europe inform development future Phase 2/3 study .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>1 . A sign informed consent form , ability understand study conduct task require study participation , willingness cooperate task , test , examination require protocol , whether hospital discharge , duration study ; 2 . Healthy adult male female 18 80 year age ( inclusive ) time screen ; 3 . Subject body mass index ( BMI ) ≥ 18.5 kg/m2 ≤ 45 kg/m2 ; 4 . Pulse measure screening/baseline must within range ≥ 45 ≤ 115 beat per minute ( bpm , take rest semirecumbent position least 5 minute ) ; 5 . Have sufficient peripheral vascular access , base Investigator 's assessment , blood sample collection take place ; 6 . Female subject surgically sterile , postmenopausal , childbearing potential , agree abstinence use least 2 acceptable method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , contraceptive patch , intrauterine device , barrier method , etc . ) male partner sterilization alone , randomization 7 day completion study ; Subjects Renal Insufficiency : 7 . Assessment renal insufficiency assignment study group base measurement estimate glomerular filtration rate calculate Modification Diet Renal Disease equation screen visit determine eligibility ; Subjects Normal Renal Function : 8 . Normal volunteer first match age ( ± 10 year ) , BMI ( ± 20 % ) , gender mean value moderate renal insufficiency group . Once mild , moderate , severe renal insufficiency group fully enrol , mean value age , BMI , gender calculate pooled renal insufficiency group , additional healthy subject may enrol match pool mean ; 9 . Have creatinine clearance ( CrCl ) ≥ 90 mL/min calculate use Cockcroft Gault equation ; Hemodialysis Subjects : 10 . Receiving stable hemodialysis ( Kt/V &gt; 1.2 ) least 3 time week least 3 month , use arteriovenous fistula graft ; 11 . Otherwise consider clinically stable respect underlie renal impairment , determine Investigator , base upon medical evaluation include medical history , physical examination , laboratory test , electrocardiogram ( ECG ) ; 12 . Have clinical laboratory test result consider clinically stable opinion Investigator , especially clinical abnormality laboratory parameter deem associated subject 's underlying renal impairment ; 13 . A stable medication regimen require , define start new drug ( ) significant change dosage ( ) within 14 day prior administration study drug , conduct study . Changes medication hemodialysis subject subject dialysis site protocol erythropoiesisstimulating agent , iron , vitamin D change base current subject status dialysis unit standard practice subject safety prior screen . 1 . Has condition , include finding medical history prestudy assessment , capable alter distribution , metabolism , elimination drug constitute risk contraindication participation study complete study ; Subjects renal insufficiency group consideration degree renal insufficiency presence comorbidities ; 2 . Current evidence history malignancy , exclude basal cell carcinoma , 2 year prior Day 1 ( day dose ) evidence recurrence ; 3 . Blood plasma donation within past 2 month ; 4 . Vigorous exercise 48 hour prior Day 1 day discharge study ; 5 . Surgery within 48 hour prior randomization surgery plan study period ; 6 . Liver function abnormality screen ( Day 1 ) ( define elevation bilirubin , aspartate aminotransferase , alanine aminotransferase 1.5 x upper limit normal normal range subject base age sex ) ; 7 . Females pregnant nursing positive pregnancy test result ; 8 . Males unwilling practice abstinence use acceptable method birth control entire study period ( i.e. , condom spermicide , locally available ) ; 9 . Presence know raise intracranial pressure ; 10 . Use isotretinoin ; 11 . History significant hypersensitivity allergic reaction tetracycline antibiotic ; 12 . History seizure ( e.g. , epilepsy ) , head injury , meningitis require ongoing antiseizure medication ; 13 . Receipt investigational medication investigational device last 30 day prior randomization ; 14 . A correct QT ( Fridericia ) &gt; 500 msec history prolong QT syndrome ; 15 . Use product contain alcohol , caffeine , xanthine , ephedrine within 48 hour dose ; 16 . Unable unwilling , judgment Investigator , comply protocol ; 17 . Subjects know active hepatitis B C , human immunodeficiency virus ( HIV ) infection know immune deficiency disease screening ; 18 . Concurrent use medication know affect elimination serum creatinine ( e.g. , trimethoprim/sulfamethoxazole [ Bactrim® ] cimetidine [ Tagamet® ] ) competitor renal tubular secretion ( e.g. , probenecid ) within 30 day prior first dose study drug anticipate need therapy last PK sample ; 19 . An employee Investigator study center sponsor , direct involvement propose study study direction Investigator study center Sponsor , family member employee Investigator . Subjects Renal Insufficiency : 20 . Have sit systolic blood pressure ( BP ) &gt; 180 mm Hg &lt; 90 mm Hg sit diastolic BP &gt; 110 mm Hg &lt; 50 mm Hg screen visit ; 21 . Use prescription nonprescription drug , vitamin , grapefruit/grapefruit juice , dietary herbal supplement within 14 day prior Day 1 list : 1 . Medications require treat underlying renal disease medical condition relate renal disease permit ; 2 . Oral contraceptive permit birth control ; 3 . Doses concomitant medication ( except hormonal contraceptive , hormone replacement therapy female , insulin ) must stable 3 week prior dose Day 1 . Minor dose change consistent treatment practice may permit discretion Sponsor 's Medical Monitor ; 4 . Acetaminophen ( ≤ 1 g/day ) low dose acetylsalicylic acid ( ASA , e.g. , ≤ 325 mg per day ) permit . Subjects Normal Renal Function : 22 . Abnormal clinically significant finding physical examination , medical history , serum chemistry , hematology , urinalysis per Investigator discretion ; 23 . Have sit systolic BP &gt; 150 mm Hg &lt; 90 mm Hg sit diastolic BP &gt; 90 mm Hg &lt; 50 mm Hg screen visit ; 24 . CrCl &lt; 90 mL/min calculate use Cockcroft Gault equation ; 25 . Use prescription nonprescription drug , vitamin , grapefruit/grapefruit juice , dietary herbal supplement within 14 day prior Day 1 list : 1 . Oral contraceptive permit birth control ; 2 . Acetaminophen ( ≤ 1 g/day ) low dose ASA ( i.e. , ≤ 325 mg per day ) permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bacterial infection</keyword>
</DOC>